Bullish & Foolish
Full PYXS fundamentals All 466 on the Survival Watch

PYXSPyxis Oncology, Inc.

Is Pyxis Oncology struggling financially?

Yes, by its own account. Pyxis Oncology told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Needs to raise money

    The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital. We will need to raise additional capital in the future.

    Form 10-Q, filed 14 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$256.9M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 5months

    If it eases off

    Empty by Nov 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$18.9M

÷

Cash burned over the last 12 months

$63.5M

What Pyxis Oncology told the SEC

…and anticipate that we will continue to incur losses over at least the next several years and may never achieve or maintain profitability. We have substantial doubt about our ability to continue as a going concern and we will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may not be able to continue…

Pyxis Oncology, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt